Viking Therapeutics Announces Positive Topline Results From Maintenance Study Of Glp-1/Gip Agonist Vk2735 Demonstrating The Promise Of Multiple Maintenance Dosing Regimens

By Reuters News

Sept 22 (Reuters) - Viking Therapeutics, Inc. VKTX.O:

  • VIKING THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM MAINTENANCE STUDY OF GLP-1/GIP AGONIST VK2735 DEMONSTRATING THE PROMISE OF MULTIPLE MAINTENANCE DOSING REGIMENS

  • VIKING THERAPEUTICS, - REPORTS 22% PLACEBO-ADJUSTED WEIGHT LOSS AT WEEK 33 WITH VK2735 17.5 MG WEEKLY DOSING

  • VIKING THERAPEUTICS, - UP TO 97% WEIGHT LOSS MAINTAINED WITH EVERY-OTHER-WEEK DOSING FOR THREE MONTHS

  • VIKING THERAPEUTICS, - UP TO 90% WEIGHT LOSS MAINTAINED WITH MONTHLY DOSING FOR THREE MONTHS

  • VIKING THERAPEUTICS, - MAINTENANCE DOSING SHOWS GI ADVERSE EVENT RATES SIMILAR TO PLACEBO

Further company coverage: VKTX.O

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.